Plural Fermentates Of Different Origin (e.g., Mixtures Of Antibiotics, Etc.) Patents (Class 424/114)
-
Publication number: 20010043926Abstract: Pharmaceutical formulations comprising amoxycillin and clavulanate in a ratio of from 10:1 to 20:1 are of use in the emperic treatement of infections potentially caused by DRSP.Type: ApplicationFiled: October 8, 1997Publication date: November 22, 2001Inventor: DANIEL JOSEPH BURCH
-
Publication number: 20010038838Abstract: Pharmaceutical formulations comprising amoxycillin and clavulanate in a ratio of from 10:1 to 20:1 are of use in the emperic treatment of infections potentially caused by DRSP.Type: ApplicationFiled: February 20, 2001Publication date: November 8, 2001Applicant: SmithKline Beecham CorporationInventor: Daniel Joseph Burch
-
Patent number: 6281191Abstract: New compositions and methods for treating patients suffering from hepatitis-C, AIDS, aberrant apoptosis which include N-acetyl-D-glucosaminyl(&bgr;-1-4)-N-Acetyl-muramyl-L-ananyl-D-isoglutamine (GMDP) of at least 98% purity and provided either alone, as an active ingredient of blastolysine, or in combination with an aminosugar such as N-acetyl-glucosamine(NAG). The high purity GMDP has a decreased amount immunogenic impurities and demonstrates cell protection as opposed to solely immunostimulatory effects, while a synergistic cell protective effect is exhibited when GMDP in combined with NAG. The new compositions modulate FasL mediated apoptosis while simultaneously stimulating TNF-&agr; production and further selectively inhibiting TNF-&agr; receptor p55 (TNFR1), providing a treatment for patients suffering from hepatitis-C, AIDS or aberrant apoptosis.Type: GrantFiled: May 13, 1999Date of Patent: August 28, 2001Inventors: Vladimir I. Slesarev, Todor Dimitrov
-
Patent number: 6277829Abstract: The present invention describes a process for the preparation of aqueous formulations containing azithromycin for ophthalmic use, as well any formulations obtained by this process and their topical use in the ocular bacterial infections, more preferably in the treatment of conjunctivitis, keratitis and blepharitis.Type: GrantFiled: December 27, 1999Date of Patent: August 21, 2001Assignee: S.I.F.I. Societa Industria Farmaceutica Italiana S.p.A.Inventors: Antonino Asero, Maria Grazia Mazzone, Valeria Moschetti, Anna Rita Blanco
-
Patent number: 6277374Abstract: A method for producing a novel yeast and mold inhibiting products (FIC) from a Lactobacillus, particularly a Lactobacillus casei having the yeast and mold producing characteristics of Lactobacillus casei var. rhamnosus NRRL-B-15972 is described. The products (FIC) are particularly useful in retarding yeast and mold growth in foods and other materials in need thereof.Type: GrantFiled: May 19, 1999Date of Patent: August 21, 2001Assignee: Microlife Technics, Inc.Inventors: Peter A. Vandenbergh, Stephen W. King
-
Patent number: 6140306Abstract: The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.Type: GrantFiled: June 3, 1996Date of Patent: October 31, 2000Assignee: Xoma CorporationInventors: Lewis H. Lambert, Jr., Roger G. Little, II
-
Patent number: 6054431Abstract: The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms. BPI protein product also increases the susceptibility of gram-positive organisms to antibiotics and can even reverse resistance of gram-positive organisms to antibiotic.Type: GrantFiled: July 20, 1998Date of Patent: April 25, 2000Assignee: XOMA CorporationInventors: Arnold Horwitz, Lewis H. Lambert, Jr., Roger G. Little, II
-
Patent number: 6015808Abstract: Pharmaceutical compositions with heretofore unknown and enhanced physical, chemical, and biological properties are prepared by combining known biologically active parent compounds with oxo thia azabicyclo compounds, such as lactam and .beta.-lactam compounds, capable of rapidly transporting the parent compounds in undegraded form to their target sites of action. A process for combining the parent compound with .beta.-lactam compounds consists of dissolving the parent compound in a polar solvent, adding a .beta.-lactam compound, incubating the resulting mixture, followed by drying, and subjecting the remaining solid material to solvent washing or extraction to further purify the new pharmaceutical composition. The new pharmaceutical composition possesses the biological and therapeutic activity of the parent compound and the barrier penetrating characteristics of the .beta.Type: GrantFiled: August 22, 1995Date of Patent: January 18, 2000Inventors: Mandayam Jeersannidhi Thirumalachar, Mandayam Jeersannidhi Narasimhan, Jr.
-
Patent number: 5998182Abstract: Disclosed are a deterioration inhibitor for an emulsion-type processing oil comprising, as an active ingredient, a culture of a bacterial species selected from the group consisting of Aerococcus viridans BC-A-4 (Acceptance No. FERM BP-5042), Bacillus brevis BC-A-69 (Acceptance No. FERM BP-5041) and Bacillus brevis BC-A-3124 (Acceptance No. FERM BP-5043) and a method for inhibiting deterioration of an emulsion-type processing oil comprising adding such deterioration inhibitor to the emulsion-type processing oil and then allowing the bacteria contained in the deterioration inhibitor to proliferate. Since the propagation of the putrefying bacteria in the emulsion-type processing oils can be suppressed by the proliferation of the bacteria contained in the deterioration inhibitor, the working life of the emulsion-type processing oil can be prolonged.Type: GrantFiled: May 9, 1997Date of Patent: December 7, 1999Assignee: Mazda Motor CorporationInventors: Hironari Nagahara, Hisao Yamasaki, Takashi Miyama, Nobuhiro Ito
-
Patent number: 5981234Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.Type: GrantFiled: June 5, 1995Date of Patent: November 9, 1999Assignee: Pharmacia & Upjohn CompanyInventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
-
Patent number: 5939066Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): ##STR1## in which: R.sup.1 is hydrogen or an organic substituent group;R.sup.2 is a fused bicyclic heterocyclic ring system of general formula: ##STR2## wherein R.sup.4 and R.sup.5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R.sup.3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol =/= indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.Type: GrantFiled: January 26, 1998Date of Patent: August 17, 1999Assignee: SmithKline Beecham p.l.c.Inventors: Kenneth Coleman, Jane Elizabeth Neale
-
Patent number: 5911985Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I), in which: R.sup.1 is hydrogen or an organic substituent group; R.sup.2 is a fused bicyclic heterocyclic ring system of general formula (a), wherein R.sup.4 and R.sup.5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R.sup.3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol .dbd./.dbd. indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier, a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.Type: GrantFiled: March 14, 1997Date of Patent: June 15, 1999Assignee: SmithKline Beecham p.l.c.Inventors: Kenneth Coleman, Jane Elizabeth Neale
-
Patent number: 5783561Abstract: The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms. BPI protein product also increases the susceptibility of gram-positive organisms to antibiotics and can even reverse resistance of gram-positive organisms to antibiotic.Type: GrantFiled: November 25, 1996Date of Patent: July 21, 1998Assignee: XOMA CorporationInventors: Arnold Horwitz, Lewis H. Lambert, Jr., Roger G. Little, II
-
Patent number: 5776455Abstract: A pharmaceutical formulation comprises, in combination with a penem of formula (I): ##STR1## in which: R.sup.1 is hydrogen or an organic substituent group;R.sup.2 is a fused bicyclic heterocyclic ring system of general formula: ##STR2## wherein R.sup.4 and R.sup.5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is zero, 1 or 2; and R.sup.3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol .dbd./.dbd. indicates that the double bond may be in either the E or Z configuration; and a pharmaceutically acceptable carrier; a .beta.-lactam antibiotic selected from the group consisting of ceftazidime, cefotaxime, amoxycillin, and piperacillin, and pharmaceutically acceptable derivatives thereof.Type: GrantFiled: June 1, 1995Date of Patent: July 7, 1998Assignee: SmithKline Beecham p.l.c.Inventors: Kenneth Coleman, Jane Elizabeth Neale
-
Patent number: 5716594Abstract: Novel biotin amide analogs that are useful for targeting therapeutic and imaging agents to sites of infection and tumors in vivo are disclosed.Type: GrantFiled: October 2, 1996Date of Patent: February 10, 1998Assignee: The JMDE TrustInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup, John W. Babich
-
Patent number: 5681563Abstract: Cephalosporins with an exocyclic allene in the 7-position and their pharmaceutically active salts are potent inhibitors of .beta.-lactamases and are therefore useful in the treatment of penicillin resistant infections.Type: GrantFiled: June 17, 1996Date of Patent: October 28, 1997Assignee: Research Corporation Technologies, Inc.Inventors: John D. Buynak, Brian Bachmann
-
Patent number: 5679789Abstract: Potassium clavulanate exists in a novel crystalline habit, namely in the form of rosettes, having improved processing properties. The novel form may, for example, be obtained by crystallization or recrystallization using inverse precipitation, preferably at 8.degree.-15.degree. C.Type: GrantFiled: June 7, 1995Date of Patent: October 21, 1997Assignee: Beecham Group, p.l.c.Inventors: Dennis Edward Clark, Shaukat Hussain Malik, Paul Gerard Butterly, Clive Elton Badman, Jeffrey David Haseler
-
Patent number: 5523288Abstract: The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.Type: GrantFiled: September 22, 1994Date of Patent: June 4, 1996Assignee: Xoma CorporationInventors: Jonathan Cohen, Ada H. C. Kung, Lewis H. Lambert, Jr., Roger G. Little, II
-
Patent number: 5514664Abstract: Optically pure diaryl compounds of formula (I), in which the substituents and symbols have the meanings indicated in the description are proposed as active ingredients in medicinal preparations for treating tumorous diseases.Type: GrantFiled: November 24, 1992Date of Patent: May 7, 1996Assignee: BYK Gulden Lomberg Chemische Fabrik GmbHInventor: Wolf-Rudiger Ulrich
-
Patent number: 5494666Abstract: Compounds of the formula ##STR1## where Z, A, and R are as disclosed herein and pharmaceutically compatible, readily hydrolyzable esters and salts of these compounds are disclosed.The compounds have .beta.-lactamase inhibiting properties and are useful in the control of .beta.-lactamase-forming pathogens in combination with .beta.-lactam antibiotics. They also exhibit antibacterial activity of their own and can accordingly be used themselves in the control or treatment of infectious diseases.Type: GrantFiled: June 9, 1995Date of Patent: February 27, 1996Assignee: Hoffmann-La Roche Inc.Inventors: Markus Bohringer, Christian Hubschwerlen, Philippe Pflieger, Jean-Luc Specklin
-
Patent number: 5464616Abstract: A 6.beta.-substituted penicillanic acid of the formula XII: ##STR1## or a pharmaceutically acceptable salt or ester thereof, whereinA and B are each hydrogen wherein the carbon atoms to which A and B are attached are linked by a single bond, or A and B together form a bond, wherein the carbon atoms to which A and B are attached are linked by a double bond,R1 is selected from the group consisting of a) hydrogen, b) a pharmaceutically acceptable salt and c) a pharmaceutically acceptable group selected from the group consisting of C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-10 cycloalkyl, C.sub.Type: GrantFiled: August 4, 1994Date of Patent: November 7, 1995Assignee: Synphar Laboratories, Ind.Inventors: Kazuharu Noguchi, Ronald G. Micetich, Mohsen Daneshtalab
-
Patent number: 5464617Abstract: Compounds of the formula ##STR1## where Z, A, and R are as disclosed herein and pharmaceutically compatible, readily hydrolyzable esters and salts of these compounds are disclosed.The compounds have .beta.-lactamase inhibiting properties and are useful in the control of .beta.-lactamase-forming pathogens in combination with .beta.-lactam antibiotics. They also exhibit antibacterial activity of their own and can accordingly be used themselves in the control or treatment of infectious diseases.Type: GrantFiled: March 3, 1995Date of Patent: November 7, 1995Assignee: Hoffmann-La Roche Inc.Inventors: Markus Bohringer, Christian Hubschwerlen, Philippe Pflieger, Jean-Luc Specklin
-
Patent number: 5340579Abstract: A method is provided for treating dermatological conditions by binding and blocking 5-a-dihydrotestosterone receptors comprising applying to the skin an effective amount of composition comprising:(a) from about 0.1% to about 2.0% by weight of mucopolysaccharides free of proteins and having a pH ranging from about 5 to 7.5 in aqueous solution, a rotary power between about to +15, and a sulfur content greater than 6%;(b) from about 1% to about 3% by weight of an aqueous extract of human umbilical cord free from sulfur and having a DH of from about 5 to about 7, a viscosity of 30.degree. C. of from 10 to 25 centistokes, a hyaluronic acid titre of from about 500 to about 700 mg/dl, and an ash content of less than about 0.5%;(c) from about 0.05 to about 0.08% by weight of tetrahydrofurfuryl nicotinate; and(d) pharmaceutically and cosmetically acceptable vehicles and excipients.Type: GrantFiled: June 20, 1990Date of Patent: August 23, 1994Assignee: Farmaka S.r.l.Inventor: Riccardo Casero, deceased
-
Patent number: 5314690Abstract: The present invention relates to a method and preparations for reducing IgE antibodies to allergens in allergic subjects wherein substance P and an allergen or fragments of allergens or haptens acting as allergens are administered together to the allergic subjects. The method can be used to treat humans and animals including dogs, cats, horses and subhuman primates.Type: GrantFiled: August 21, 1992Date of Patent: May 24, 1994Assignee: Northwestern UniversityInventors: Roy Patterson, Kathleen E. Harris
-
Patent number: 5275816Abstract: 7 .alpha.-formamido cephalosporin derivatives having a 3[N-(optionally substituted)aminothiopyridinium thiomethyl] substituent have anti-bacterial activity and are of use in anti-bacterial therapy. Processes for the preparation thereof and intermediates for use in these processes are also disclosed.Type: GrantFiled: September 4, 1990Date of Patent: January 4, 1994Assignee: Beecham Group p.l.c.Inventors: Clive L. Branch, Angela W. Guest, Stephen C. Finch
-
Patent number: 5258373Abstract: Compositions comprising a mixture of the antibiotic frenolicin B with a potentiated sulfonamide anticoccidial agent, useful for the treatment and prevention of coccidiosis in animals and methods of treating coccidiosis are disclosed.Type: GrantFiled: July 17, 1991Date of Patent: November 2, 1993Assignee: Hoffmann-La Roche Inc.Inventors: Eugene G. Schildknecht, Govind G. Untawale
-
Patent number: 5124150Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: March 11, 1991Date of Patent: June 23, 1992Assignee: Bristol-Myers Squibb Co.Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5108747Abstract: A pharmaceutical preparation comprising an antibiotic, a pharmaceutical excipient therefor, and in addition an oxapenem-3-carboxylic acid of the formula ##STR1## or a pharmaceutically acceptable salt, ester or amide in which R.sup.1 and R.sup.2 each independently is hydrogen or a pharmaceutically acceptable group having 1 to 10 carbon atoms which is connected with the balance of the molecule via carbon-carbon single bonds, and in whichR.sup.3, R.sup.4 and R.sup.5 each independently is a pharmaceutically acceptable group having 1 to 10 carbon atoms which is connected with the balance of the molecule via carbon-carbon single bonds.Type: GrantFiled: September 27, 1989Date of Patent: April 28, 1992Assignee: Bayer AktiengesellschaftInventors: Hans-Rudolf Pfaendler, Karl G. Metzger, Rainer Endermann, Ingo Haller, Hanno Wild, Wolfgang Hartiwg
-
Patent number: 5098708Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.Type: GrantFiled: July 6, 1990Date of Patent: March 24, 1992Assignee: Bristol-Myers Squibb CompanyInventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
-
Patent number: 5064649Abstract: .beta.-Lactam antibiotics of the formula (Ia) or a pharmaceutically acceptable salt or pharmaceutically acceptable in vivo hydrolysable ester thereof are disclosed: ##STR1## wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is a acyl group, in particular that of an antibacterially active cephalosporin; CO.sub.2 R.sup.6 is carboxy group or a carboxylate anion; R.sup.4 is a butenolide or butanolide ring, optionally substituted by one or two alkyl, dialkylamino, alkoxy, hydroxy or aryl groups, which may be the same or different, or, wherein two adjacent carbon atoms which are available for substitution define the common bond of an aromatic fused bicyclic system; X is S, SO, SO.sub.2, O or CH.sub.2 ; and the dashed line adjacent to R.sup.4 represents an optional double bond. Processes for the preparation of compounds together with intermediates for use therein are disclosed.Type: GrantFiled: September 14, 1989Date of Patent: November 12, 1991Assignee: Beecham Group p.l.c.Inventors: George Burton, Stephen C. M. Fell, John H. Bateson
-
Patent number: 5064821Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs 13-(substituted mercapto) derivatives of tetracycline in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously or concurrently. The concomittantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state. The combination also effects a synergistic bacteriocidal activity against susceptible and resistant cells.Type: GrantFiled: February 26, 1990Date of Patent: November 12, 1991Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy
-
Patent number: 5028427Abstract: .beta.-Lactam antibiotics have the formula (Ia) or are pharmaceutically acceptable salts or pharmaceutically acceptable in vivo hydrolysable esters thereof: ##STR1## in which the group CO.sub.2 R.sup.1 is carboxy or a carboxylate anion. The use of the compounds and processes for their preparation are disclosed.Type: GrantFiled: August 22, 1988Date of Patent: July 2, 1991Assignee: Beecham Group p.l.c.Inventor: Stephen C. Finch
-
Patent number: 5015473Abstract: Beta-lactamase inhibiting compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition or carboxylate salt thereof; where n is zero, 1 or 2; X.sub.3 is H or Br, R.sup.1 is H, the residue of certain carboxy-protecting groups or the residue of an ester group readily hydrolyzable in vivo; one of R.sup.12 and R.sup.13 is H and the other is vinyl, certain aryl, alkylthio, alkylsulfonyl or certain heterocyclyl, aminomethyl, thiocarboxyamido or amidino groups; one of R.sup.2 and R.sup.3 is H and the other is as disclosed for the other of R.sup.12 and R.sup.13, or is Cl or CH.sub.2 OH, and R.sup.18 is H or certain acyl groups; intermediates useful in their production, methods for their preparation and use, and pharmaceutical compositions containing them.Type: GrantFiled: January 13, 1989Date of Patent: May 14, 1991Assignee: Pfizer Inc.Inventor: Yuhpyng L. Chen
-
Patent number: 4999195Abstract: Personal care products comprising bioemulsifiers, for example, those produced by Acinetobacter calcoaceticus, are provided. Use of such personal care products result in beneficial effects to skin and hair.Type: GrantFiled: July 5, 1989Date of Patent: March 12, 1991Assignee: Emulsan Biotechnologies Inc.Inventor: Michael E. Hayes
-
Patent number: 4956179Abstract: An antibacterial synergistic composition consisting essentially of a mixture of a penicillin or cephalosporin derivative of the formula ##STR1## and a penicillin of the formula ##STR2## preferably in association with a pharmaceutical carrier.Type: GrantFiled: July 2, 1987Date of Patent: September 11, 1990Assignees: Astra Lakemedel Aktiebolag, Astra Pharmaceutical Products, Inc.Inventors: Peter Bamberg, Bertil A. Ekstrom, Ulf E. Forsgren, Berndt O. H. Sjoberg
-
Patent number: 4956374Abstract: Novel antifungal antibiotic compounds have the structural formula ##STR1## A preferred compound where R is 4-hydroxypentyl is denoted BU-3557B.sub.2. A complex of said compounds is produced by fermenting a culture of Sacchrothrix aerocolonigenes strain N806-4 (ATCC 53712). The complex is recovered by adsorption on nonionic porous polymer resin adsorbent and individual component compounds exhibit in vitro activity against fungi and Gram-positive bacteria and BU-3557B.sub.2 demonstrates in vitro antiprotazoal activity. BU-3557B.sub.2 demonstrates in vivo activity against C. albicans vaginal infection and BU-3557A.sub.3 (where R is 1,5-dihydroxy-5,5-dimethylpentyl) demonstrates in vivo activity against C. albicans systemic infection.Type: GrantFiled: July 29, 1988Date of Patent: September 11, 1990Assignee: Bristol-Myers CompanyInventors: Maki Nishio, Shigeyuki Ando, Takeo Miyaki, Masataka Konishi, Toshikazu Oki
-
Patent number: 4952397Abstract: Compounds of the formula: ##STR1## wherein ##STR2## is a quaternized, monocyclic or bicyclic heteroaryl group, substituted by an acid moiety, and their preparation and use as antibiotics are disclosed.Type: GrantFiled: November 23, 1988Date of Patent: August 28, 1990Assignee: Merck & Co., Inc.Inventors: James V. Heck, Ronald W. Ratcliffe
-
Patent number: 4938959Abstract: An ear powder and/or drop, containing soluble substances and an insoluble substance which will be spread of the mucous membrane and form a deposit which will act by its physical acitivity as a dilution support for powder active principles and as a sponge for drops.Type: GrantFiled: August 30, 1988Date of Patent: July 3, 1990Assignee: Georges Serge GrimbergInventors: Henri A. Martin, Maurice Carraz, Rene Mallein, Georges S. Grimberg
-
Patent number: 4919932Abstract: A pharmaceutical formulation having a synergistic anti-bacterial activity and comprising(a) a cephalosporin derivative or a physiologically acceptable salt or ester thereof and(b) a penem antibiotic of the basic structure (B) ##STR1## or a physiologically acceptable salt or ester thereof, a process for preparing such a formulation and its use for the treatment of bacterial infections.Type: GrantFiled: June 2, 1987Date of Patent: April 24, 1990Assignee: Hoechst AktiengesellschaftInventors: Michael Limbert, Elmar Schrinner, Gerhard Seibert
-
Patent number: 4911924Abstract: Microorganisms carrying tetracycline-resistant determinants are hypersensitized to Sm- and 2-DOS- aminoglycoside antibiotics by exposure to subinhibitory amounts of tetracycline inducer.Type: GrantFiled: April 17, 1987Date of Patent: March 27, 1990Assignee: University of New MexicoInventors: Jeffrey K. Griffith, William L. Anderson
-
Patent number: 4898731Abstract: An antibacterial synergistic composition consisting essentially of a mixture of a penicillin or cephalosporin derivative of the formula ##STR1## and a penicillin of the formula ##STR2## preferably in association with a pharmaceutical carrier.Type: GrantFiled: June 24, 1985Date of Patent: February 6, 1990Assignees: Astra Lakemedel Aktiebolag, Astra Pharmaceutical Products, Inc.Inventors: Peter Bamberg, Bertil A. Ekstrom, Ulf E. Forsgren, Berndt O. H. Sjoberg
-
Patent number: 4870010Abstract: Personal care products comprising bioemulsifiers, for example, those produced by Acinetobacter calcoaceticus, are provided. Use of such personal care products result in beneficial effects to skin and hair.Type: GrantFiled: April 15, 1986Date of Patent: September 26, 1989Assignee: Petroleum Fermentations N.V.Inventor: Michael E. Hayes
-
Patent number: 4822608Abstract: Methods and compositions are described for the treatment of mammalian infections, including bacterial, viral and cancerous infections, in which hymenoptera venom or proteinaceous or polypeptide components thereof are employed to enhance the activity of primary anti-bacterial, anti-viral, anti-carcinogenic or carcinostatic agents.Type: GrantFiled: September 14, 1987Date of Patent: April 18, 1989Assignee: Vespa Laboratories, Inc.Inventors: Allen W. Benton, Lorraine Mulfinger
-
Patent number: 4743619Abstract: The invention disclosed herein provides a method of treating an animal infected by hepatitis B virus comprising administering to such infected animal an amount of a rifamycin derivative selected from a group consisting of(a) 3-amino-4-deoxo-4-imino-rifamycin S,(b) 3-amino-4-deoxo-4-[(4-aminophenyl)sulfonyl]amino-rifamycin SV,(c) 4-O-(n-butylsulfonyl)-3-[(1-piperidinylimino)methyl]-rifamycin SV,(d) 4-O-(n-butylsulfonyl)-3-[(4-morpholinylimino)methyl]-rifamycin SV,(e) 3-[(dimethylhydrazono)methyl]-4-O-[(3-phenylpropyl)sulfonyl]-rifamycin SV, and(f) 4-deoxo-N,3-ethylidenimino-4-(methylsulfonyl)amino-rifamycin SV, said amount being effective to alleviate the effects of said hepatitis B virus. Also disclosed is a method of inhibiting the viral polymerase of hepatitis B virus by subjecting said polymerase to an amount of one of the rifamycin derivatives (a)-(f) above, said amount being effective to prevent the synthesis of hepatitis B virus by said viral polymerase.Type: GrantFiled: August 25, 1986Date of Patent: May 10, 1988Assignee: American Home Products CorporationInventor: Paul P. Hung
-
Patent number: 4689227Abstract: The antibacterially-active substance composition consisting of mecillinam and (2S,3S)-3-((Z)-2-(2-amino-4-thiazolyl)-2-((carboxymethoxy)imino)acetamido) -2-((carbamoyloxy)methyl-4-oxo-1-azetidinesulphonic acid (compound A), or pro-drugs and/or pharmaceutically usable salts thereof, has a pronounced synergism against Enterobacter strains which are resistant to mecillinam and which are only moderately sensitive to compound A.Type: GrantFiled: July 24, 1986Date of Patent: August 25, 1987Assignee: Hoffmann-La Roche Inc.Inventor: Peter Angehrn
-
Patent number: 4684643Abstract: The instant invention is a pharmaceutical composition suitable for storage in plastic containers which comprises a pharmaceutical compound in powder form coated with a surfactant. A second aspect of the invention is a method for making the composition. This method encompasses applying a solution of a surfactant to the surface of a pharmaceutical compound in powder form and then drying the composition.Type: GrantFiled: June 3, 1985Date of Patent: August 4, 1987Assignee: Eli Lilly and CompanyInventors: Harry C. Buddenbaum, Robert L. Robison
-
Patent number: 4675186Abstract: 6-(1-Acyl-1-hydroxymethyl)penicillanic acid derivatives are useful as antibacterials and/or beta-lactamase inhibitors.Type: GrantFiled: March 11, 1986Date of Patent: June 23, 1987Assignee: Pfizer Inc.Inventor: Lawrence A. Reed, III, deceased
-
Patent number: 4668514Abstract: This invention provides a penicillin derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different and represent hydrogen, C.sub.1-6 alkyl, C.sub.1-6 hydroxyalkyl, C.sub.3-9 acyloxyalkyl, C.sub.8-13 benzyloxyalkyl, C.sub.2-7 alkoxyalkyl, C.sub.2-7 alkoxycarbonyl, C.sub.3-8 alkenyloxycarbonyl, C.sub.3-8 alkynyloxycarbonyl, phenyl, amino, cyano, formyl, trifluoromethyl, C.sub.2-6 acyl, carbamoyl, C.sub.2-7 alkylcarbamoyl, benzyloxycarbonylamino, C.sub.2-7 alkoxycarbonylamino; and R.sub.3 is hydrogen, a group for forming a pharmaceutically acceptable salt, or a penicillin carboxyl protecting group, with the proviso that both of R.sub.1 and R.sub.2 are not hydrogen or C.sub.2-7 alkoxycarbonyl at the same time and that when one of R.sub.1 and R.sub.2 is hydrogen, the other is not C.sub.2-7 alkoxycarbonyl, or a pharmaceutically acceptable acid addition salt, process for preparing the derivative, and a pharmaceutical composition containing the derivative.Type: GrantFiled: October 5, 1984Date of Patent: May 26, 1987Assignee: Taiho Pharmaceutical Company LimitedInventors: Ronald G. Micetich, Shigeru Yamabe, Motoaki Tanaka, Tomio Yamazaki, Naobumi Ishida, Makoto Kajitani
-
Patent number: 4665067Abstract: Disclosed are compounds of the general formula: ##STR1## wherein R.sub.1 is amino, an acylated amino or a protected amino group, X is hydrogen or methoxy, and R' is hydrogen, R or R.sup.4 wherein R is an organic residue attached to the azetidine ring through a carbon atom therein and R.sub.4 is azido, a halogen, an amino group which may optionally be acylated or a group of the formula --OR.sub.5, ##STR2## or --S--S--R.sub.5 wherein R.sub.5 is an organic residue and n is 0, 1 or 2, and pharmaceutically acceptable salts and esters thereof.The compounds have antimicrobial and/or .beta.-lactamase-inhibitory activity and are of value as drugs for human beings and domesticated animals.Type: GrantFiled: June 5, 1985Date of Patent: May 12, 1987Assignee: Takeda Chemical Industries, Ltd.Inventors: Shoji Kishimoto, Taisuke Matsuo, Michihiko Ochiai
-
Patent number: 4652560Abstract: The compounds of the formula (II): ##STR1## or pharmaceutically acceptable salts or esters thereof wherein A is a hydrogen atom or an esterifying radical; X is an alkyl group of 1-12 carbon atoms optionally substituted by a hydroxy, amino, acylamino of C.sub.1-6 alkoxy group, which substituents are not on the carbon atom adjacent to the nitrogen atom; or a C.sub.5-7 cycloalkyl group; or a phenylalkyl group wherein the carbon atom content of the alkyl part is 1-6 and the phenyl part is optionally substituted with a fluorine, bromine, chlorine, C.sub.1-6 alkyl, or C.sub.1-6 alkoxy; with the proviso that when X represents an optionally substituted phenylalkyl group and A represents C.sub.1-3 alkyl, then the --CO.sub.2 A group is attached to the alkyl part of the phenylalkyl group; have been found to be .beta.-lactamase inhibitors and antibacterial agents. Their preparation and use is described.Type: GrantFiled: April 13, 1983Date of Patent: March 24, 1987Assignee: Beecham Group p.l.c.Inventors: Brian P. Clarke, John B. Harbridge, Irene Stirling